Savara (SVRA) Retained Earnings (2010 - 2026)
Savara (SVRA) posted quarterly Retained Earnings of -$645.4 million for Q1 2026, down 25.1% year-over-year from -$861.7 million in Q1 2025, and down 6.14% quarter-over-quarter from -$608.1 million in Q4 2025.
Savara (SVRA) Retained Earnings (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Retained Earnings for 17 consecutive years, with -$645.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 25.1% year-over-year to -$645.4 million; the TTM figure through Mar 2026 stood at -$645.4 million (down 25.1% YoY), while the FY2025 annual figure was -$608.1 million, down 24.29% from the prior year.
- Retained Earnings declined to -$645.4 million in Q1 2026 per SVRA's latest filing, from -$608.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$461000.0 in Q1 2023 and bottomed at -$645.4 million in Q1 2026.
- Historically, Retained Earnings has averaged -$354.5 million across 5 years, with a median of -$393.4 million in 2023.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 115328.07% — and 2023, when it surged 99.85%.
- Savara's Retained Earnings stood at -$605000.0 in 2022, then tumbled by 64919.67% to -$393.4 million in 2023, then declined by 24.37% to -$489.2 million in 2024, then declined by 24.29% to -$608.1 million in 2025, then decreased by 6.14% to -$645.4 million in 2026.
- Business Quant data shows SVRA's Retained Earnings at -$645.4 million in Q1 2026, -$608.1 million in Q4 2025, and -$575.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | -685.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -685.60 Mn |
| Mar 31, 2026 | -645.40 Mn |
| Dec 31, 2025 | -608.09 Mn |
| Sep 30, 2025 | -575.90 Mn |
| Jun 30, 2025 | -546.29 Mn |
| Mar 31, 2025 | -515.90 Mn |
| Dec 31, 2024 | -489.25 Mn |
| Sep 30, 2024 | -460.21 Mn |
| Jun 30, 2024 | -880,000.00 |
| Mar 31, 2024 | -413.72 Mn |
| Dec 31, 2023 | -393.37 Mn |
| Sep 30, 2023 | -377.30 Mn |
| Jun 30, 2023 | -360.67 Mn |
| Mar 31, 2023 | -461,000.00 |
| Dec 31, 2022 | -605,000.00 |
| Sep 30, 2022 | -328.40 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Mar 31, 2022 | -308.82 Mn |
| Dec 31, 2021 | -300.52 Mn |
| Sep 30, 2021 | 285,000.00 |